Wanbury Ltd
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
- Market Cap ₹ 838 Cr.
- Current Price ₹ 255
- High / Low ₹ 330 / 154
- Stock P/E 19.5
- Book Value ₹ 18.1
- Dividend Yield 0.00 %
- ROCE 34.9 %
- ROE 70.0 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 29.8% CAGR over last 5 years
Cons
- Stock is trading at 14.1 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 10.3% over past five years.
- Tax rate seems low
- Promoters have pledged or encumbered 76.7% of their holding.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Sep 2014 18m | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 500 | 576 | 600 | 630 | |
620 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 476 | 506 | 523 | 542 | |
Operating Profit | 41 | 21 | 34 | 19 | -68 | 16 | 23 | 18 | 36 | 23 | 70 | 76 | 88 |
OPM % | 6% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 12% | 13% | 14% |
-237 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | 0 | 3 | 3 | 5 | |
Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
Profit before tax | -267 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 31 | 30 | 42 |
Tax % | 1% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | |
-270 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 30 | 31 | 43 | |
EPS in Rs | -135.21 | 1.61 | -3.52 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 9.28 | 9.32 | 13.10 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 5% |
TTM: | 12% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 30% |
3 Years: | 78% |
TTM: | 61% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | 46% |
3 Years: | 54% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 70% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
Reserves | -186 | -188 | -183 | -151 | -183 | -207 | -143 | -156 | -30 | -40 | -5 | 26 |
389 | 381 | 373 | 273 | 224 | 233 | 164 | 166 | 74 | 68 | 116 | 177 | |
182 | 182 | 176 | 265 | 207 | 235 | 231 | 253 | 275 | 241 | 199 | 178 | |
Total Liabilities | 404 | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 |
174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | |
CWIP | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
218 | 212 | 192 | 215 | 83 | 103 | 99 | 109 | 182 | 133 | 174 | 208 | |
Total Assets | 404 | 394 | 386 | 411 | 271 | 285 | 277 | 288 | 351 | 302 | 343 | 414 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
74 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | 26 | |
-7 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 | |
-75 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | 26 | |
Net Cash Flow | -9 | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 50 | 57 | 70 |
Inventory Days | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
Days Payable | 112 | 300 | 171 | 259 | 173 | 208 | 252 | 220 | 218 | 178 | 196 | 172 |
Cash Conversion Cycle | -13 | -54 | -37 | -124 | -117 | -131 | -176 | -147 | -112 | -101 | -96 | -55 |
Working Capital Days | -44 | -139 | -123 | -164 | -251 | -230 | -211 | -227 | -134 | -129 | -38 | 4 |
ROCE % | 6% | 12% | 55% | -1% | 26% | 31% | 23% | 46% | 17% | 58% | 35% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2d - Wanbury Q1 FY26 revenue ₹163.2 Cr (+24%), PAT ₹13.5 Cr (+1198%), ₹85 Cr CAPEX approved for FY26.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
4 Aug - Q1 FY25-26 results approved; 91,500 ESOPs granted; director re-appointed; 3 inactive subsidiaries closure initiated.
-
Un-Audited Financial Results
4 Aug - Q1 FY25 results approved; director reappointed; 91,500 ESOPs granted; closure of 3 inactive foreign subsidiaries.
-
Announcement under Regulation 30 (LODR)-Change in Management
4 Aug - Q1 FY25 results approved; 91,500 ESOPs granted; Chairman reappointed; closure of 3 inactive foreign subsidiaries.
-
Board Meeting Outcome for Outcome Of The Board Meeting
4 Aug - Q1 FY25 results approved; 91,500 ESOPs granted; director re-appointed; 3 inactive subsidiaries closure initiated.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence